tbuckley/cabot-search huggingface dataset:
ALLERGY IN MALARIA
Authors: Harvey F. Grazier
Journal: Annals of Internal Medicine (1946)

Case Reports1 December 1946ALLERGY IN MALARIAHARVEY F. GRAZIERHARVEY F. GRAZIERSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-25-6-968 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe various manifestations of malarial infection are common knowledge, but specific sensitivity to the protein of the malarial parasite is almost a medical curiosity. References to such a condition in the available literature are very few, and detailed case reports almost non-existent. The relationship between urticaria and malarial infection has been infrequently observed over the past 25 years, but as late as 1939 the possibility of urticaria existing coincidentally with and not related to malarial infection was under discussion. In 1928 Thonnard-Neumann described cases in Haiti in which treatment of malaria cured coexistent asthma. More recently urticaria as a result...Bibliography1. ALBUQUERQUE SOARES HD: Sindrome urticariforme na malaria, Brasil-med., 1942, lvi, 431. Google Scholar2. CHATTERJEE SC: Urticaria in malarial infection, Calcutta Med. Jr., 1939, xxxv, 291-293. Google Scholar3. GOURIOU E: Eruption morbilliforme et urticaire d'origine palustre, Bull. Soc. path. exot., 1938, xxxi, 614-617. Google Scholar4. NIKOLAVO ND: Le paludisme chez les enfants au point de vue de l'allergie, Pediatria. 1939, 41-46. Google Scholar5. SABLIN PE: Le paludisme sous le jour de la conception d'allergie, Vrach. delo., 1937, xix, 519-522. Google Scholar6. SEN GUPTA PC: Urticaria due to malarial infection, Indian Med. Gaz., 1942, lxxvii, 416. Google Scholar7. SHIRAKOGOROV IL: Pathomorphology of malaria from the view point of allergic reactions, Vrach. delo., 1936, xix, 345-354. Google Scholar8. THONNARD-NEUMANN E: Malaria und asthma, Arch. f. Schiffs-u. Tropen-Hyg., 1928, xxxii, 358-362. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication August 10, 1945. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 December 1946Volume 25, Issue 6Page: 968-971KeywordsAllergy and immunologyAsthmaMalariaProteinsUrticaria ePublished: 1 December 2008 Issue Published: 1 December 1946 PDF downloadLoading ...
Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS
Authors: T.J.M. de Witte, A. van Biezen, J. Hermans, M. Labopin, V. Runde, R. Or, G. Meloni, S.B. Mauri, A. Carella, J. Apperley, A. Gratwohl, J. Laporte
Journal: Blood (1997)
Prenatal Fetal DNA Testing for Predicting HDFN, FNAIT, and RhIG Candidacy
Authors: C. Ellen van der Schoot, Florentine Thurik, Peter G. Scheffer, Frithjofna Abbink, van der Ploeg P.B. Catharina, Barbera Veldhuisen, Masja de Haas
Journal: Blood (2013)
Abstract 1813: A novel designed small peptide enhances chemotherapy sensitivity of leukemia cells in stromal microenvironment
Authors: Xiaojin Li, Hua Guo, Yanlian Yang, Jie Meng, Jian Liu, Chen Wang, Haiyan Xu
Journal: Cancer Research (2014)

Abstract Many types of leukemia cells highly express chemokine receptor (CXCR4) that actively responses to CXCL12, a chemokine constitutively secreted by stromal cells in bone marrow. Activation of CXCR4 induces leukemia cells trafficking and homing to the marrow microenvironment, where CXCL12 retains these cells in close contact with marrow stromal cells that provide growth, self-renewal, and drug resistance signals, which lead to poor prognosis and relapse. We report here a novel designed peptide targeting to CXCR4, named as XW1108-3. The patented sequence is GGQGCRFRNTVDD WISITRAL. We use flow cytometry, cell migration and adhesion assay to study the affinity of XW1108-3 to leukemia cells and the inhibitory effect on CXCL12-induced cell behaviors. The XW1108-3 shows high affinity to different types of leukemia cell highly expressing CXCR4 including HL-60, NB4, THP-1 and U937, the binding was maintained for up to 4 hours. The XW1108-3 treatment significantly inhibited CXCL12- or murine stromal cell MS-5-induced migration of leukemia cells in a concentration dependent manner in the transwell assay and significantly reduced the leukemia cells adhesion to MS-5 cell layer. Mechanistic study with western blot and confocal microscopy assay demonstrates that XW1108-3 treatment down regulates CXCL12-induced phosphorylation of Erk, Akt and p38 and affects F-actin organization, resulting in the suppression of the cell response to CXCL12 activation. It is notable that XW1108-3 treatment did not induce apoptosis of leukemia cells or human fibroblasts and endothelial cells even at 10 µM, instead enhanced the level of 10-hydroxy camptothecin-induced apoptosis of different leukemia cells co-incubated with the stromal cell MS-5 layer, thereby exhibiting great clinical implications in leukemia chemotherapies and immune therapies. Citation Format: Xiaojin Li, Hua Guo, Yanlian Yang, Jie Meng, Jian Liu, Chen Wang, Haiyan Xu. A novel designed small peptide enhances chemotherapy sensitivity of leukemia cells in stromal microenvironment. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1813. doi:10.1158/1538-7445.AM2014-1813
Abstract 2426: Relationship Between Invasive Hemodynamics And Peripheral Blood Mononuclear Cell Gene Expression After Heart Transplantation In The Absence Of Moderate Or Severe Acute Cellular Rejection
Authors: Martin Cadeiras, Khurram Shahzad, Farhana Latif, Sreevalsa Unniachan, Anshu Sinha, Manuel Bayern, Charles C Marboe, Mario C Deng
Journal: Circulation (2008)
LYMPHOSARCOMA OF THE THYROID: REPORT OF A CASE
Authors: S D CONKLIN, D H GENT
Journal: Annals of Internal Medicine (1957)

Case Reports1 April 1957LYMPHOSARCOMA OF THE THYROID: REPORT OF A CASESTANLEY D. CONKLIN, M.D., DONALD H. GENT, M.D., F.A.C.P.STANLEY D. CONKLIN, M.D.Search for more papers by this author, DONALD H. GENT, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-46-4-784 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptPrimary lymphosarcoma of the thyroid is a rare disease. Review of the literature reveals a total of only 33 cases. Dinsmore1reported eight patients at the Cleveland Clinic. Pool2reported on two cases. Means3had three cases which he thought arose in the thyroid gland. Pemberton4reported on four among 774 patients in his series. Rice5reported five cases. Ade6reported on one case apparently arising in a chronic thyroiditis. De Quervain7also had one case of struma maligna. Wegelin8claims to have observed nine cases since 1933, but in two cases that he describes in detail there is such...Bibliography1. DinsmoreDempseyHazard RSWSJB: Lymphosarcoma of thyroid, J. Clin. Endocrinol. 9: 1043-1047 (Oct.) 1949. CrossrefGoogle Scholar2. Pool EH: Malignant growths of thyroid, Ann. Surg. 85: 120-128 (Jan.) 1927. CrossrefMedlineGoogle Scholar3. Means JH: The thyroid and its diseases, 2nd Ed., 1948, J. B. Lippincott Company, Philadelphia. Google Scholar4. Pemberton Jd: Malignant lesions of thyroid gland; review of 774 cases, Surg., Gynec. and Obst. 69: 417-430 (Oct.) 1939. Google Scholar5. Rice CO: Das Lymphosarkom der Schilddrüse, Virchows Arch. f. path. Anat. 286: 459-475, 1932. CrossrefGoogle Scholar6. Ade B: Thyroïdite chronique atrophiante lymphocytaire évoluant en lymphosarcome, Helvet. med. acta 8: 352-376, 1941. Google Scholar7. De Quervain , as cited by Wegelin, C.8 Google Scholar8. Wegelin C: Eigenartige Metastasen beim Lymphosarkom der Schilddrüse, Schweiz. Ztschr. f. Path. u. Bakt. 9: 687-691, 1946. MedlineGoogle Scholar9. Anderson WA: Pathology, 1948, C. V. Mosby Company, St. Louis, p. 1075. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Sayre, Pennsylvania*Received for publication November 22, 1955.From the Department of Internal Medicine, Guthrie Clinic-Robert Packer Hospital, Sayre, Pennsylvania.Requests for reprints should be addressed to Stanley D. Conklin, M.D., Guthrie Clinic, Sayre, Pennsylvania. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThyroid Lymphoma with gastrointestinal involvement: Report of three casesMalignant lymphoma of the thyroid 1 April 1957Volume 46, Issue 4Page: 784-788KeywordsAdenomasHospital medicineLesionsLymphomaSarcomaThyroidThyroidectomy Issue Published: 1 April 1957 PDF downloadLoading ...
Effectiveness and safety of fumaric acid esters in children with psoriasis: a retrospective analysis of 14 patients from the Netherlands
Authors: D.M.W. Balak, A.M. Oostveen, M.T. Bousema, A.W. Venema, W.P. Arnold, M.M.B. Seyger, H.B. Thio
Journal: British Journal of Dermatology (2013)

Fumaric acid esters (FAE) are used as an effective and safe oral treatment for plaque psoriasis in adult patients, but little is known about their efficacy and safety in children with psoriasis.To assess the effectiveness and safety of FAE in the treatment of paediatric psoriasis.This is a retrospective analysis of 14 paediatric patients with psoriasis (age <18 years) treated with FAE between 2004 and 2012 at several Dutch university and regional clinics. Patients were identified through databases or registries.The median age at the start of FAE treatment was 15 years (range 8-17 years). The median duration of FAE treatment was 10 months (range 1-80 months), and the median maintenance dosage per day was 360 mg dimethylfumarate (range 240-600 mg). Five patients (36%) achieved a complete clearance of their psoriasis, one patient (7%) had a good improvement, three patients (21%) had a partial response and five patients (36%) were nonresponders. FAE treatment was well tolerated, but two patients (14%) discontinued FAE, one with severe diarrhoea and one with flushes. Five patients (36%) had transient, slightly abnormal laboratory values of liver-function tests or leucocytes that did not necessitate FAE dosage reduction or treatment discontinuation. No serious adverse events occurred.In this retrospective case series FAE seemed to be an effective and safe treatment for children with psoriasis. FAE may be an attractive therapeutic alternative to the currently used systemic immunosuppressive agents for paediatric patients with psoriasis. Further studies are needed to evaluate the suitability of FAE in paediatric psoriasis.
Abstract 3574: Analysis of whole genome and transcriptome sequencing in single cell
Authors: Nak-Jung Kwon, Woo Chung Lee, Jiwoong Kim, Hyeri Kim, Ahreum Seong, Bong Cho Kim, Doo Hyun Park, Kap-Seok Yang
Journal: Cancer Research (2014)

Abstract The rapid advancement in Next Generation Sequencing (NGS) technology has allowed extensive genetic profiling and analysis of tumor tissues. While accurate tumor characterization is crucial for cancer therapy, current sequencing methods are unable to resolve the genetic differences between the heterogeneous cell populations within tumor. By profiling specific subpopulations of cells from a larger heterogeneous population, single cell sequencing can improve the efficiency of cancer treatments through early detection of rare tumor cells, monitoring of circulating tumor cells, and accurate profiling of intra-tumor heterogeneity. In this study, we compared commercially available single cell amplification methods and sequencing platforms for whole genome and whole transcriptome sequencing. We isolated single cells from a human breast cancer cell line, MCF7, and human embryonic kidney cell line, HEK293, by micromanipulation, and their whole genome and transcriptome were sequenced. For whole genome sequencing, the performance of Repli-g (Qiagen), Ampli1 (Slicon Biosystems) and WGA4 (Sigma) were assessed for whole genome amplification. Next, we used TruSeq DNA Library Kit and Ion Plus Fragment Library Kit for library preparation, and whole genome sequencing was performed on HiSeq2000 and Proton. The sequencing data were analyzed by SAMtools/GATK and tmap-f3. For whole transcriptome sequencing, cDNA was synthesized from single cells using SMARTer ultra low input RNA kit (Clontech), and the cDNA library was prepared with Nextera XT library prep kit (Illumina) and Ion Total RNA-Seq Kit v2 (Life Technologies). Sequencing was performed on HiSeq2000 and Proton, and analyzed with Tophat and Cufflink. We show that the percentage of mappable reads and regions with more than 1X coverage in whole genome sequencing were similar to that of the genomic DNA data, but the coverage rate of regions with more than 10X was lower in single cell data on both NGS platforms. In the RNA-Seq, the gene detection rate in single cell and more than 100 cells were about 65% and 85% compare to total RNA, respectively. Citation Format: Nak-Jung Kwon, Woo Chung Lee, Jiwoong Kim, Hyeri Kim, Ahreum Seong, Bong Cho Kim, Doo Hyun Park, Kap-Seok Yang. Analysis of whole genome and transcriptome sequencing in single cell. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3574. doi:10.1158/1538-7445.AM2014-3574
Neurally adjusted NIV improves patient-ventilator interaction in COPD
Authors: Jonne Doorduin, Christer A. Sinderby, Jennifer Beck, Johannes G. Van der Hoeven, Leo M.A. Heunks
Journal: European Respiratory Journal (2014)

Background: Non-invasive ventilation (NIV) still frequently fails in managing acute respiratory failure. Amongst the reasons for NIV failure is poor patient-ventilator interaction (PVI). Neurally adjusted ventilatory assist (NAVA) is a ventilator mode that uses electrical activity of the diaphragm (Edi) to control ventilation. There are no studies of PVI during NIV-NAVA in strictly COPD patients, while these patients are most likely to exhibit poor PVI. Therefore, our aim was to compare PVI between NAVA and conventional modes in COPD patients.   Methods: Twelve COPD patients were ventilated for 30 minutes with: PSV with the BiPAP Vision (dedicated NIV ventilator); PSV with the Servo-I (ICU ventilator); and NAVA. PVI was evaluated by comparing airway pressure and Edi with computer algorithms.   Results:  Figure 1 depicts individual trigger delays and cycle-off errors for each mode. Figure 2 plots the distribution of synchrony, dyssynchrony and asynchronies for each mode.   Conclusion:  This study shows that NIV-NAVA synchronizes assist to inspiratory effort in COPD patients, whereas PSV (with dedicated and ICU ventilator) does not ensure acceptable patient-ventilator interaction.
Clinical Paralytic Poliomyelitis Due to Coxsackie Virus Group A, Type 7
Authors: Edwin R. Ranzenhofer, FE C. Dizon, Murray M. Lipton, Alex J. Steigman
Journal: New England Journal of Medicine (1958)

THE following case represents apparently the first clinical confirmation, outside Russia, of paralytic disease caused by Coxsackie virus Group A, Type 7.Case ReportA 3-year-old boy entered Children's Hospital, Louisville, on July 9, 1956, because of stiff neck, vomiting and walking "stiff legged" for a day. He was noted to have a temperature of 103°F., nuchal rigidity and positive Kernig and Brudzinski signs, without any paresis. The clear spinal fluid revealed 245 white cells per cubic millimeter (68 per cent polymorphonuclear leukocytes and 32 per cent lymphocytes), with a total protein of 32 mg. and sugar of 56 mg. . . .
Respiratory Function in Disease: An Introduction to the Integrated Study of the Lung.
Authors: David V. Bates, Peter T. Macklem, Ronald V. Christie, Nicholas R. Anthonisen
Journal: Annals of Internal Medicine (1965)

Respiratory function in disease; an introduction to the integrated study of the lung , Respiratory function in disease; an introduction to the integrated study of the lung , دانشگاه علوم پزشکی ایران
对《处方管理办法》中若干问题的解读(一)
Authors: 吴永佩
Journal: BMJ (2008)

一、医师开具处方可使用哪些药品名称？ 《处方管理办法》（《办法》）规定医师开具处方可使用的药品名称： （1）药品通用名称，即药品制剂通用名称。 （2）新活性化合物的专利药品名称，即原研发企业生产的药品专利药品名称。
Abstract 2703: Clinical and neurohormonal correlates and prognostic value of Kansas City Cardiomyopathy Questionnaire in patients with chronic heart failure
Authors: Maria Nikolaou, John Parissis, Dimitrios Farmakis, Vasiliki Bistola, Koula Venetsanou, Kallirhoe Kourea, Gerasimos Filippatos, Dimitrios Kremastinos
Journal: Circulation (2007)

Chronic heart failure (CHF) is characterized by limited exercise activity, enhanced immune activation, and increased morbidity and mortality. Although quality of life and physical activity assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ functional and overall) have been used for the clinical evaluation of CHF patients, the prognostic value as well as the relationship of this questionnaire with neurohormonal/immune activation remain uknown. Methods: One hundred thirty seven consecutive stable CHF patients (aged 64 ± 12 yrs, mean NYHA class: 2.9 ± 0.6, mean left ventricular ejection fraction: 26±7% ) were evaluated by the above questionnaire, Zung 20-item self rating and Beck Depression Inventory (BDI) scales, Duke physical activity score, plasma BNP, plasma cytokines (IL-6, IL-10 and TNF-a) and 6-min walking test. Patients were monitored for a 8-month follow-up period for disease progression defined as death and/or hospitalization. Results: The mean KCCQ functional and overall scores were 44±20% and 33±19%, respectively. Patients (n=41) with KCCQ overall score &lt;50% had significantly higher Zung (46±10 vs 34±9, p&lt;0.01) and BDI (18±10 vs 8±6, p&lt;0.01) scales, plasma BNP (900±801 vs 543±374 pg/ml, p&lt;0.05) and plasma IL-6 (12.7±7 pg/ml vs 8.5±6.4 pg/ml, p&lt;0.05) as well as lower DUKE score (15±10 vs 28±13, p&lt;0.01), 6-min walking distance (259±200 vs 363±113 m, p&lt;0.001) and plasma anti-inflammatory cytokine IL-10 (6.1±3.2 pg/ml vs 9.4±5.4 pg/ml, p &lt;0.05) as compared to those (n=96) with score &gt;50%. KCCQ overall score was significantly corellated with plasma BNP levels (r=-0.42, p&lt;0.01), 6-min walking distance (r=0.47, p&lt;0.01) and BDI scale (r=-0.61, p&lt;0.001). Finally, patients with KCCQ overall score &gt;50% had longer event-free survival (182±13 vs 122±15 days, p&lt;0.05) than those with score &lt;50%. Conclusion: KCCQ is a valuable tool for the evaluation of severity of clinical and emotional symptoms of CHF patients, closely related with their neurohormonal/immune activation and seems to have important prognostic value in CHF.
Abstract 2623: PI3K/mTOR dual inhibitor PF-5212384 inhibits aberrant NF-kB activation and exhibits activity in combination with MEK inhibitor PD-325901 and docetaxel in human head and neck squamous cell carcinoma
Authors: Suresh Mohan, Robert J. Vander Broek, Anthony D. Saleh, Matthew L. Pierce, Jamie F. Coupar, Danielle F. Eytan, Zhong Chen, Carter Van Waes
Journal: Cancer Research (2014)

Abstract Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, and standard treatment with surgery or chemoradiation has significant morbidity, with 5 year survival of &amp;lt;50%. Personalized targeted therapies with small molecule inhibitors have gained interest following identification of genetic drivers from The Cancer Genome Atlas (TCGA). TCGA data shows &amp;gt;60% of head and neck tumors harbor genomic alterations in the RTK-PI3K-mTOR and MAPK pathways important in cell growth and survival. In this study, we determined the effects of the novel PI3K-mTOR inhibitor PF-5212384 (PF-384) on molecular targets and HNSCC growth in preclinical models. PF-384 IC50s of 0.75nM-133nM were found in 12 HNSCC lines by XTT cell density assays and treatment resulted in increased sub-G0 cell death and G0/G1 phase blockade by DNA flow cytometry. PF-384 strongly inhibited direct targets of PI3K-mTOR, aberrant NF-kB transactivation and induced cytokines, but only partially inhibited MEK pathway targets. Transient siRNA knockdown of PIK3CA inhibited NF-kB activity, supporting PI3K-mTOR as an important driver and target for inhibition of NF-kB prosurvival signaling in HNSCC. PF-384 partially inhibited UMSCC1 tumor xenografts in vivo. PF-384 with MEK inhibitor PD-325901 or docetaxel revealed combinatorial activity. Given the high proportion of HNSCC patients with aberrations in the PI3K pathway and combinatorial activity observed, PF-384 with PD-901 or docetaxel merit further investigation in HNSCC. Supported by NIH Medical Research Scholars Program (SM, RVB, DFE) and NIDCD intramural projects ZIA-DC-000016, 73 and 74 (AS, JC, ZC, CVW). Citation Format: Suresh Mohan, Robert J. Vander Broek, Anthony D. Saleh, Matthew L. Pierce, Jamie F. Coupar, Danielle F. Eytan, Zhong Chen, Carter Van Waes. PI3K/mTOR dual inhibitor PF-5212384 inhibits aberrant NF-kB activation and exhibits activity in combination with MEK inhibitor PD-325901 and docetaxel in human head and neck squamous cell carcinoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2623. doi:10.1158/1538-7445.AM2014-2623
Tumor Induction by Genetically Homogeneous Lines of Polyoma Virus&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Ernest Winocour, Leo Sachs
Journal: JNCI Journal of the National Cancer Institute (1961)

Polyoma virus, reisolated from mouse parotid, kidney, and mammary-tumor cells in culture, has been purified by 3 successive single plaque isolations. Inoculation of the third-passage single plaque isolates into hamsters, mice, and rats can result in the development of multiple tumors. Homogeneous lines of polyoma virus are therefore capable of inducing more than one tumor type. Plaque-purified virus of kidney and mammary-tumor origin induced parotid tumors in mice to the same degree as virus initially isolated from the parotid-tumor cells. However, virus of kidney-tumor origin appeared to have a greater ability for producing multiple tumors in AKR mice than virus of parotid-tumor origin. Data have been obtained which suggest that the dosage, in addition to its effect on the proportion of animals developing tumors, also appears to determine how many of these will develop multiple tumors after inoculation with plaque-purified virus. The results have also provided further evidence that there is a difference in susceptibility of different strains of mice. With the use of the same plaque-purified virus at the same dosage level, AKR mice had a much higher susceptibility than SWR mice, but C57BL/6 mice in these experiments were completely resistant to tumor induction. Thus, despite the fact that the same plaque-purified virus can produce tumors in different rodents, there still appears to be some strain specificity in mice.